Citigroup
PBYI icon

Citigroup’s Puma Biotechnology PBYI Stock Holding History

Citigroup’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-31,800
Closed -$326K – 7099
2020
Q4 		$326K Buy
31,800
+14,900
+88% +$151K ﹤0.01% 4587
2020
Q3 		$171K Sell
16,900
-3,800
-18% -$38.7K ﹤0.01% 4728
2020
Q2 		$216K Sell
20,700
-11,300
-35% -$117K ﹤0.01% 4954
2020
Q1 		$270K Sell
32,000
-67,800
-68% -$659K ﹤0.01% 4470
2019
Q4 		$873K Buy
99,800
+5,500
+6% +$45.5K ﹤0.01% 3904
2019
Q3 		$1.01M Buy
94,300
+34,500
+58% +$373K ﹤0.01% 3631
2019
Q2 		$760K Buy
59,800
+6,900
+13% +$159K ﹤0.01% 3984
2019
Q1 		$2.05M Buy
52,900
+39,500
+295% +$1.21M ﹤0.01% 2612
2018
Q4 		$273K Buy
13,400
+6,700
+100% +$201K ﹤0.01% 4720
2018
Q3 		$307K Sell
6,700
-10,900
-62% -$526K ﹤0.01% 4813
2018
Q2 		$1.04M Sell
17,600
-6,200
-26% -$359K ﹤0.01% 3316
2018
Q1 		$1.62M Buy
23,800
+8,200
+53% +$614K ﹤0.01% 2793
2017
Q4 		$1.54M Buy
15,600
+200
+1% +$22.4K ﹤0.01% 2916
2017
Q3 		$1.84M Sell
15,400
-12,500
-45% -$1.16M ﹤0.01% 2736
2017
Q2 		$2.44M Buy
27,900
+22,100
+381% +$1.24M ﹤0.01% 2394
2017
Q1 		$216K Sell
5,800
-16,700
-74% -$609K ﹤0.01% 4604
2016
Q4 		$691K Sell
22,500
-8,800
-28% -$380K ﹤0.01% 4047
2016
Q3 		$2.1M Buy
31,300
+26,100
+502% +$1.32M ﹤0.01% 2466
2016
Q2 		$155K Buy
5,200
+5,100
+5,100% +$159K ﹤0.01% 4719
2016
Q1 		$3K Sell
100
-1,900
-95% -$85.9K ﹤0.01% 7139
2015
Q4 		$157K Buy
2,000
+100
+5% +$7.85K ﹤0.01% 4959
2015
Q3 		$143K Buy
+1,900
New +$180K ﹤0.01% 4750
2014
Q4 		– Sell
-30,000
Closed -$7.16M – 7257
2014
Q3 		$7.16M Buy
+30,000
New +$6.16M 0.01% 1555

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's PBYI Position: Q2 2026 in Review

Citigroup increased its Puma Biotechnology (PBYI) stake by 533% in Q2 2026, buying an estimated $134K and bringing the position to 21,666 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #4407.

Citigroup first reported a position in PBYI in Q3 2013 and has held it in 50 quarters since. The position peaked at $6.77M in Q4 2017. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Citigroup held 21,666 shares of Puma Biotechnology worth $176K as of Q2 2026.
  • Citigroup bought 18,244 Puma Biotechnology shares in Q2 2026, an estimated $134K.
  • Puma Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4407 holding.
  • Citigroup first reported a position in Puma Biotechnology in Q3 2013 and has held it in 50 quarters since.
  • Citigroup's Puma Biotechnology position peaked at $6.77M in Q4 2017.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.